Pneumocystis has a large multicopy gene family encoding proteins related to the major surface glycoprotein (Msg), whose functions are largely unknown. We expressed one such protein of Pneumocystis murina, p57, which is encoded by 3 highly conserved genes, and demonstrated by immunoblot that immunocompetent mice that were immunized with crude Pneumocystis antigens or that had cleared Pneumocystis infection developed antibodies to p57. Using hyperimmune anti-p57 serum combined with immunolabeling, we found that p57 was expressed by small trophic forms and intracystic bodies, whereas it was not expressed on larger trophic forms or externally by cysts. Expression of p57 and Msg by trophic forms was largely mutually exclusive. Treatment of infected animals with caspofungin inhibited cyst formation and markedly decreased p57 expression. While p57 expression was seen in immunocompetent mice infected with Pneumocystis, immunization with recombinant p57 did not result in altered cytokine expression by lymphocytes or in diminished infection in such mice. Thus, p57 appears to be a stage-specific antigen of Pneumocystis that is expressed on intracystic bodies and young trophic forms and may represent a mechanism to conserve resources in organisms during periods of limited exposure to host immune responses.
Recombinant p57 Protein Expression
A P. murina p57 gene (PNEG_02419; GenBank accession number XM_007876234.1) lacking the leader sequence and hydrophobic tail was synthesized with codon optimization for expression in mammalian cells (Genscript). The optimized p57 gene (encoding amino acids 20-486) was subsequently cloned into bacterial expression vectors pET28 (Novagen), pGEX-6P-1 (GE Healthcare), and pMALc2X (New England Biolabs), modified with the addition of a histidine tag and kindly provided by Dr Peter Burbelo. It was also cloned into a mammalian expression vector, pcDNA3.1 (Invitrogen), modified to include a FLAG tag at the amino terminus and a His tag at the carboxyl terminus (pcDNAL1). p57-pET28, p57-pGEX-6P-1, and p57-pMALHis were expressed in BL21-codon plus (DE3)-RIL cells, and p57-pcDNAL1 was expressed in COS cells. p57-pcDNAL1 and p57-pMALHis were purified using a Ni-NTA agarose (Qiagen) column.
Immunization
Healthy C57BL/6 mice were immunized subcutaneously with 20 µg of recombinant p57 antigen (from p57-pcDNAL1), using Freund's complete adjuvant, and were boosted with 3 additional injections (1 every 2-3 weeks), using Freund's incomplete adjuvant. Approximately 2 weeks after the last injection, blood specimens were collected for separation of serum, and spleens were collected for analysis by cell proliferation assays.
To see whether immunization with p57 could protect healthy mice from Pneumocystis infection, mice were immunized 3 times as described above (ie, 20 µg/injection) with recombinant p57 (from p57-pMALHis; n = 10) or with adjuvant alone (controls; n = 9) before exposure to P. murina as described below.
Pneumocystis Infection
Immunocompetent C57BL/6 mice, which develop a limited infection with Pneumocystis prior to clearance, and CD40L KO mice, which are highly susceptible to Pneumocystis infection, were infected with P. murina by cohousing them with a CD40L KO seeder mouse infected with a large load of P. murina, as previously reported [3] . Animals were euthanized at various time points after exposure, and serum and lungs were collected. A portion of the lungs was placed in phosphate-buffered saline and used to quantitate organism load by quantitative polymerase chain reaction (qPCR) analysis [3] , and a portion was placed in HistoChoice fixative with 20% ethanol (Amresco, Solon, OH), for immunofluorescence labeling studies. P. murina that was partially purified from ground lung samples of CD40L KO mice by Ficoll-Hypaque gradient centrifugation [17] was also used for immunofluorescence labeling of intact organisms. For evaluation of p57 expression in caspofungin-treated mice, we used lungs from mice from a previously reported study, in which caspofungin was administered by intraperitoneal injection at a dose of 10 mg/kg/day 5 days per week for 21 days [10] .
For vaccine studies, following immunization as described above, mice from each group were cohoused with infected CD40L KO seeder mice and euthanized at either day 35-36 or day 77 of exposure; lungs and serum specimens were then collected. Pneumocystis organisms were quantitated by qPCR. In a subset of animals, cytokine production by CD4 + and CD8 + T cells was characterized by flow cytometry as described below [18] . Antibodies to p57 were evaluated by immunoblot analysis as described below.
qPCR
The Pneumocystis organism load was determined by qPCR analysis as previously described, using the single-copy dihydrofolate reductase (dhfr) gene of P. murina as the target. Results are expressed as dhfr copies per milligram of lung tissue [3] .
qPCR was also used to compare the relative expression of p57 messenger RNA, normalized to P. murina 18S ribosomal RNA levels, using the ∆∆Ct method, among different groups of animals (3-4 animals/group) [19] . Additional details are provided in the Supplementary Methods.
Immunoblot
Immunoblots were performed as previously described [20] , using recombinant p57 or partially purified P. murina organisms disrupted with glass beads. Additional details are provided in the Supplementary Methods.
Cell Proliferation Assay
Spleen cell proliferation was measured as previously described [20] . Mouse spleen cells were cultured in 96-well plates (100 000 cells/well) with concanavalin A (2.5 µg/mL) for 4 days as a positive control and with crude P. murina antigens (100 µg/mL), normal lung antigens (100 µg/mL), or no antigen for 5 days, after which the level of proliferation was determined using the CellTiter-Glo Luminescent Cell Viability Assay (Promega).
Flow Cytometry
Flow cytometry and intracellular cytokine staining for interferon γ, interleukin 17, interleukin 4, and interleukin 5 were performed as previously described [18] . Additional details are provided in the Supplementary Methods.
Immunofluorescence and Microscopic Imaging
P. murina organisms partially purified by Ficoll-Hypaque gradient centrifugation were heat fixed onto slides; probed with anti-p57 hyperimmune sera, anti-P. murina sera (as a positive control), or sham-immunized sera (as a negative control); and then incubated with Alexa Fluor 488-labeled donkey antimouse immunoglobulin G (IgG). Images were captured on a Nikon Eclipse E800.
P. murina-infected and uninfected control lung tissues fixed in HistoChoice (Amresco, Solon, OH) were embedded in paraffin, and 5-to 10-µm sections were labeled with mouse anti-p57 hyperimmune serum, rabbit anti-Msg hyperimmune serum (generated to recombinant Msg107Am and Msg119Am [20] To compare the sizes of different stages of Pneumocystis organisms, organisms labeled with anti-Msg, anti-p57, and anti-β-1,3 glucan (n = 40 for each) were measured (from the outer edge to the outer edge) along the longest axis on a single image slice of a z-stack, using one z-stack for p57 and Msg and 3 z-stacks for β-1,3 glucan.
Phylogenetic Analysis
p57 homologs in the genomes of Pneumocystis jirovecii, Pneumocystis carinii, and P. murina were extracted (n = 16) [5] . Sequences were aligned using MUSCLE v3.8.31 [21] and manually inspected. To recover distant homologs, hidden Markov Models were prepared using HMMER3 [22] and used to screen the proteomes (HMMSEARCH e-value cutoff, 10 -5 ). A total of 29 new putative remote homologs were retrieved and added to the original sequences for alignment and were manually inspected using Jalview 2 [23] . Phylogenetic analyses were performed using MrBayes v.3.2.5 (10 million generations) [24] and RAxML v8.2.5 with 1000 bootstrap as support values [25] with the -m PROTGAMMAAUTO option (best-scoring AA model: FLU likelihood). Sequences, alignment, and tree are available at: http://doi.org/10.5281/zenodo.1068332.
Statistical Analysis
Pneumocystis organism sizes, qPCR results, and organism loads and cytokine expression between immunized and unimmunized mice were compared using the Student t test.
RESULTS

During sequencing of 3 Pneumocystis genomes [5]
, we identified 3 highly conserved P. murina genes, PNEG_02059, PNEG _02419, and PNEG _03592 (GenBank accession numbers XP_007874040.1, XP_007874425.1, and XP_007875686.1, respectively), that encoded p57, a member of the Msg superfamily ( Figure 1 ). We found a gene that encoded a closely related protein (T552_02796; GenBank accession number XP_018225130.1; approximately 56% identity; Figure 1 ) and Figure 1 . Multiple sequence comparison by log-expectation alignment of the 3 highly conserved Pneumocystis murina p57 proteins (PNEG_02419, PNEG_02059, and PNEG_03592) and a single Pneumocystis carinii p57 protein (T552_02796). P. murina has 3 copies of p57, which are located on 3 different chromosomes and are 95%-99% identical at the amino acid level. P. carinii has a single copy of p57, which has approximately 56% identity to P. murina p57 at the amino acid level. Conserved residues are shaded.
was present as a single copy in the P. carinii genome. Although the P. jirovecii genome contains multiple genes encoding Msg superfamily proteins of approximately the same size, no highly similar protein was identified. By Bayesian analysis, the most closely related protein was T551_02050 (approximately 25% identity; GenBank accession number XP_018229667.1).
Given that p57 was predicted to be a surface protein and thus a potential antigen of Pneumocystis, we expressed one of these proteins, PNEG_02419, using recombinant methods. Initially we expressed it by using the pET28 vector, but expression levels were low, detectable by immunoblot but not visible by protein stain following sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Subsequently, large quantities of recombinant p57 protein were obtained by expression in pcD-NAL1 and pMalHis vectors, followed by purification using a Ni-NTA agarose column. Recombinant p57 from all sources migrated, when analyzed by SDS-PAGE, at a higher than predicted molecular weight (eg, p57-pcDNAL1, shown in Figure 2 , migrated a distance equivalent to that of protein with a molecular weight of approximately 98 kDa but has a predicted molecular weight of 56 kDa). Proteomic analysis by mass spectrometry of purified p57-pMalHis protein in the presence of DTT, which, during SDS-PAGE, migrated a distance suggestive of a molecular weight of approximately 130 kDa, demonstrated a molecular weight of approximately 97 000 Da, consistent with the predicted molecular weight of 97 kDa (data not shown). This suggests that rp57, regardless of the vector used, runs aberrantly in SDS-PAGE analyses.
To determine whether p57 was an antigen of P. murina, we performed immunoblot assays with recombinant protein, using sera from C57BL/6 mice that had been infected with and successfully cleared P. murina infection or that had been immunized with crude P. murina antigens. As shown in Figure 2 , both sets of animals reacted with recombinant p57, while no reactivity was seen with serum from a sham-immunized mouse, indicating that native p57 induces an antibody response following either infection or immunization.
Given that p57 is a newly identified antigen of Pneumocystis, we wanted to characterize its expression by P. murina. To facilitate this, C57BL mice were immunized with purified recombinant p57-pcDNAL1, to obtain hyperimmune sera to use in immunofluorescent labeling studies, as well as to examine antibody and T-cell proliferative responses in immunized animals. As shown in Figure 3 , anti-p57 hyperimmune sera showed reactivity by immunoblot with recombinant p57, as well as with crude P. murina antigen, indicating that recombinant p57 is immunogenic. Similar to recombinant p57, native protein Figure 2 . Pneumocystis murina-immunized and P. murina-exposed mice have antibodies against p57 protein. Recombinant p57 was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and stained with Coomassie blue or was evaluated by immunoblot by using an anti-His monoclonal antibody or mouse sera. For both gel and blots, lane 1 contains rp57 protein expressed in Cos cells and purified using a Ni-NTA column, and lane 2 contains Cos cell lysate as a negative control. Anti-His tag antibody reacts predominantly with a protein band running near the 98-kDa molecular weight standard (arrow). Serum from a mouse immunized with a crude P. murina antigen preparation and from a mouse that cleared P. murina infection following exposure by cohousing both demonstrated reactivity with rp57, whereas serum from a mouse immunized with adjuvant alone (sham immunized) shows no reactivity. The location of molecular weight markers, in kilodaltons, is shown on the left. were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. Serum from a p57-pcDNA-immunized mouse demonstrates reactivity with rp57 lysate at approximately 120 kDa (larger than the predicted size of 79 kDa) but not with the control lysate; serum from a sham-immunized mouse shows no reactivity. rp57 expressed in pGEX-6P1 was used for immunoblot analysis because it has no expressed vector sequence in common with the immunizing vector (no His tag and no FLAG tag). B, Crude P. murina antigens (partially purified P. murina organisms disrupted with glass beads) were separated by SDS-PAGE and transferred to a polyvinylidene difluoride membrane. The blots were probed with serum from 2 mice immunized with rp57-pcDNAL1 (lanes 1 and 2) or with serum from a control mouse immunized with adjuvant alone (lane 3). p57 hyperimmune sera reacts with a band of approximately 100 kDa, larger than the predicted size. No similar reactivity is seen with the control serum. The location of molecular weight markers, in kilodaltons, is shown on the left. migrated slower than predicted, with an apparent molecular weight of approximately 100 kDa, suggesting it is either a dimer or migrating aberrantly. However, splenocytes from mice immunized with recombinant p57 that were then cultured with crude native P. murina antigens did not show a T-cell proliferative response (data not shown).
To determine whether p57 was expressed on the surface and whether it was expressed on all forms of the organism, we immunofluorescently labeled partially purified intact organisms. As shown in Figure 4 , many organisms from a heavily infected lung were labeled, demonstrating that p57 was a surface-expressed protein. Notably, all labeled organisms appeared to be smaller than the organisms typically labeled with an anti-Msg antibody. On the basis of morphologic analysis, cysts did not appear to be labeled; however, since the β-1,3 glucan in cysts is largely masked by surface proteins in these preparations [10] , we could not colabel with an anti-β-1,3 glucan antibody to definitively demonstrate this.
To better characterize the Pneumocystis forms expressing p57, we immunolabeled HistoChoice-fixed, paraffin-embedded lung tissue sections from a mouse with a large Pneumocystis load, using anti-p57 and anti-β-1,3 glucan antibodies. Again we found that p57 was primarily expressed by smaller organisms, which appeared to be trophic forms ( Figure 5A ). However, while cysts as identified by anti-β-1,3 glucan labeling did not express p57 on their surface, p57 was expressed on intracystic bodies in some but not all cysts ( Figure 5A ).
We next determined whether p57 colocalized with Msg, since we had anticipated that Msg would be expressed by all Pneumocystis organisms. As shown in Figure 5B , we unexpectedly found that trophic forms expressed either Msg or p57 but rarely expressed both on the same organism. Similarly, in cysts, Msg was expressed exclusively on the outer cell wall surface, while p57 was expressed only on intracystic bodies. Thus, p57 appears to be a stage-specific antigen of P. murina that is expressed exclusively on intracystic bodies and small trophic forms that we hypothesize have been recently released from cysts.
We measured organisms labeled with the 3 markers to compare sizes of different stages (n = 40 for each). p57-positive organisms (mean diameter [±SD], 1.35 ± 0.28 µm) were significantly smaller than both Msg-positive (3.73 ± 0.65 µm) and β-1,3 glucan-positive (4.23 ± 0.52 µm) organisms (P < .0001 for both); Msg-positive organisms were also smaller than β-1,3 glucan-positive organisms (P = .0003).
Caspofungin is a drug that inhibits β-1,3 glucan synthase in Pneumocystis and other fungi and can prevent the formation of cysts nearly completely in infected lungs [26] [27] [28] .
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Anti-P. murina antigens Nonimmune serum To examine our hypothesis that p57 is expressed in a stage-specific manner, we immunolabeled lung tissue sections from a P. murinainfected CD40L KO mouse treated with caspofungin for 21 days, a point at which only rare cysts can be detected by anti-β-1,3 glucan labeling [10] . As shown in Figure 6A , p57 expression was markedly decreased in caspofungin-treated animals. Immunocompetent C57BL/6 mice become transiently infected with P. murina before clearance [3] . To see whether p57 was expressed during the low-level infection seen in these animals, lung sections from infected C57BL/6 mice were labeled as described above. As seen in Figure 6B , p57 expression was present in the rare small clusters of infection in C57BL/6 mice.
We used qPCR to determine whether there were differences in p57 RNA expression levels in caspofungin-treated versus untreated CD40L KO mice and in immunocompetent C57BL/6 mice versus CD40L KO mice. We found no significant differences in either comparison, although there was a modest decrease in caspofungin-treated versus untreated animals (fold change = 0.83; P = .3) but not in C57BL/6 mice versus CD40L KO mice (fold change = 0.99; P = .9).
A B Figure 5 . Anti-rp57 serum reacts with a subset of Pneumocystis murina organisms, as demonstrated by immunofluorescence microscopy. A, P. murina-infected CD40L knockout (KO) mouse lung tissue sections were dual labeled using anti-p57 (green) and anti-β-1,3 glucan (magenta) antibodies. p57 is not expressed on the surface of cysts, which are identified by the anti-β-1,3 glucan antibody, but is expressed on intracystic bodies of some cysts (inset). p57 is also expressed on multiple small organisms that are presumably trophic forms. The broken line box outlines the cyst magnified in the inset, where p57 antibody labeling of the intracystic bodies is apparent. The main and inset images are both maximum projections of a 5-µm-thick z-stack imaged on a Nikon 90i epifluorescence microscope and deconvolved. B, Labeling multiple life stages of Pneumocystis, using anti-major surface glycoprotein (Msg) antibody (red) and anti-p57 (green). Although Msg is present on both cysts and trophic forms, p57 and Msg expression appear to be largely mutually exclusive. p57 is expressed by smaller organisms, while Msg is expressed by larger trophic forms, as well as cysts. The broken line box outlines a cyst (based on morphology) that is magnified in the inset as a single slice from the same z-stack, again demonstrating labeling of intracystic bodies but not the cyst surface. The main image is a maximum projection of an 8-µm-thick z-stack imaged on a Leica SP8 confocal microscope. All images have DAPI (blue). The bars denote 10 µm in the main images and 2 µm in the insets. A more detailed figure showing individual labeling for all markers, as well as a merge, is provided in the Supplementary Data.
A B C Figure 6 . Immunofluorescence microscopy of Pneumocystis murina-infected CD40L knockout (KO) and C57BL/6 mouse lung tissue. All sections were labeled with anti-p57 antibody (green), anti-major surface glycoprotein antibody (red), and anti-β-1,3 glucan (magenta). A, Lung section from a CD40L KO mouse treated with caspofungin for 21 days. Cysts are largely eliminated, and, in conjunction with that, there is very limited expression of p57. B, Lung section from a P. murina-infected C57BL/6 mouse 28 days after the start of cohousing. Although the peak level of infection is typically 2-3 log 10 less than in CD40L KO mice, p57 expression is easily identified. C, Lung section from a C57BL/6 mouse immunized with p57-pMALHis and subsequently infected with P. murina. p57 expression is again easily identified, and the level of infection in immunized animals is similar that in unimmunized animals (see also Figure 7 ). All images are maximum projections of approximately 6-µm-thick z-stacks imaged on the Nikon 90i microscope and deconvolved. The bar is 10 µm. A more detailed figure showing individual labeling for all markers and DAPI, as well as a merge, is provided in the Supplementary Data.
Since p57 was expressed by Pneumocystis in immunocompetent mice, we wanted to determine whether immunization with p57 prior to exposure protected such mice from infection or limited the organism burden. C57BL/6 mice were immunized 3 times with p57-pMALHis and then cohoused with Pneumocystis-infected CD40L KO mice. After 35-36 days, which corresponds to the approximate time of peak infection in these mice, p57-immunized mice had a mean infection level (±standard error of the mean) similar to that for adjuvant immunized controls (6536 ± 1663 and 4379 ± 767 dhfr copies/mg lung tissue, respectively; P = .3; Figure 7A ). Of note, p57-expressing organisms were easily identified by immunolabeling lung tissues from immunized animals ( Figure 6C ) and were present at levels visually equivalent to levels in unimmunized controls. By day 76-77, both groups had largely cleared infection.
Immunoblot analysis confirmed that all p57-immunized animals had a strong anti-p57 antibody response and that the adjuvant-alone controls had no detectable responses ( Figure 7B ). Further, flow cytometry analysis of T-helper type 1 (Th1), Th2, and Th17 CD4 + T-cell subsets in the lungs showed no difference between p57-immunized and control animals at day 36, with predominantly Th1 and Th17 responses in both groups and minimal Th2 responses (Supplementary Table 1) , consistent with our previously reported results [18] . Similarly, analysis of IFN-γ production by CD8 + T cells at day 36 showed no significant difference between the groups. Intriguingly, p57-immunized mice had higher cytokine responses at day 77 as compared to sham-immunized mice or uninfected control mice on day 77, although since there were only 2 animals per group, the significance is uncertain (Supplementary Table 1 ).
DISCUSSION
In this study, we identified a new antigen of P. murina, p57, which is expressed in only a subset of organisms and in what appears to be a stage-specific manner. In immunosuppressed mice infected with a large number of Pneumocystis, p57 expression is limited to intracystic bodies and to what morphologically appear to be small trophic forms. Similar forms were also seen in immunocompetent mice, which have a reduced level of infection.
It is noteworthy that Msg and p57 expression are mutually exclusive. Although both are members of the Msg superfamily [5] , Msg is a larger protein that is encoded by a multicopy gene family (the Msg-A1 subfamily [5] ) and that confers on Pneumocystis the potential for antigenic variation [12, 14] . Given that intracystic bodies are protected from host exposure by the cyst wall, which potentially obviates the need for evasion of host immune responses, we hypothesize that Pneumocystis expresses p57 rather than Msg in that setting since Msg expression will require more cellular resources and is more complex, given that gene conversion may be a fundamental mechanism for expressing Msg variants [14] . Once the intracystic bodies are released, they presumably shift from expressing p57 to expressing a classical Msg variant; thus, p57 expression would be limited to recently released, presumably smaller (younger), trophic forms. An alternative explanation-that the small extracystic forms are precursors to conjugation and cyst formation-seems less likely, based on the hypothesized life cycle of Pneumocystis [9] .
To determine whether p57 expression is dependent on the presence of cysts, we examined the lungs of animals treated with caspofungin, an inhibitor of β-1,3 glucan synthase, which markedly depletes cysts after 21 days of treatment. In support of our hypothesis that expression is life-cycle specific, p57 expression was markedly diminished in heavily infected immunodeficient mice treated with caspofungin, suggesting that p57 expression is dependent on the presence of cysts. Although relative messenger RNA expression as determined by qPCR was not significantly decreased in caspofungin-treated animals, this may be related to use of RNA regulatory mechanisms to control gene expression, which appears to be important in Pneumocystis organisms [5] . p57 is also expressed by organisms infecting immunocompetent hosts, and relative expression is similar to that in immunodeficient hosts. Since p57 appears to be expressed at least transiently after release of intracystic bodies from cysts, we immunized C57BL/6 mice with p57 to see whether the generated immune response would protect immunocompetent animals from infection. However, we found that, despite the induction of strong antibody responses to p57 in immunized mice, as detected by immunoblot, immunization offered no protection; all immunized animals were infected and had organism loads similar to those in unimmunized mice. Moreover, we saw no differences in pulmonary CD4 + T-helper cell responses between the 2 groups at the peak of infection. Although we did not do more-detailed kinetic studies to see whether the time course of infection or clearance was influenced by immunization, these data suggest that the transient exposure of p57 to the host environment is insufficient to allow antibodies to interrupt the Pneumocystis life cycle or that antibodies are not effective in clearing p57-expressing organisms.
Homologues of p57 are likely expressed by other Pneumocystis species. A gene encoding a closely related protein was identified in the P. carinii genome, and a possible candidate gene was identified in the P. jirovecii genome, as well. All 3 species have genes encoding additional Msg family proteins of a similar size (ie, the Msg-E family [5] ), although their expression has not been extensively studied. One related protein, p55 of P. carinii, requires lyticase treatment of organisms to expose it to antibodies, suggesting a different function than p57, although the life forms expressing it have not been well characterized [29] .
This study highlights the complexity of expression of Msgrelated proteins and the potential mechanisms Pneumocystis has developed to minimize cellular energy and resource expenditures. Additional studies are needed to characterize the expression of other Msg family members and to better understand their role in the Pneumocystis life cycle and host interactions.
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